Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 20/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1921020 | 0.93 | TLR7 (0.53) | TLR7 | |
| SCHEMBL2197923 | 0.92 | TLR7 (0.63) | TLR7 | |
| SCHEMBL2197899 | 0.91 | TLR7 (0.67) | TLR7 | |
| SCHEMBL2197902 | 0.91 | TLR7 (0.59) | TLR7 | |
| SCHEMBL1920709 | 0.90 | TLR7 (0.54) | TLR7 | |
| SCHEMBL1952039 | 0.88 | TLR7 (0.51) | TLR7 | |
| SCHEMBL1919115 | 0.88 | TLR7 (0.54) | TLR7 | |
| SCHEMBL2198602 | 0.86 | TLR7 (0.62) | TLR7 | |
| SCHEMBL2199223 | 0.86 | TLR7 (0.66) | TLR7 | |
| SCHEMBL2198548 | 0.85 | TLR7 (0.58) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575181-B2 | Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases | GLAXOSMITHKLINE LLC (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575181-B2 | Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases | GLAXOSMITHKLINE LLC (US) | 2013-11-05 | — | — | US | disclosed |
| EP-2326646-B1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | GLAXOSMITHKLINE LLC (US) | 2013-07-31 | — | — | EP | disclosed |
| US-20110135670-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | GLAXOSMITHKLINE LLC (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110135670-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | GLAXOSMITHKLINE LLC (US) | 2011-06-09 | — | — | US | disclosed |
| EP-2326646-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | Smithkline Beecham Corporation (US) | 2011-06-01 | — | — | EP | disclosed |
| WO-2010018130-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135670-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | IFNAR1, IFNG, STING1 | TLR7 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.